Top

Published in:

12-12-2023 | Primary Biliary Cholangitis | Leading Article

New Therapies on the Horizon for Primary Biliary Cholangitis

Author: Atsushi Tanaka

Published in: Drugs | Issue 1/2024

Abstract

Primary biliary cholangitis (PBC) is a chronic cholestatic liver disease that can progress to cirrhosis and hepatic failure if left untreated. Ursodeoxycholic acid (UDCA) was introduced as a first-line drug for PBC around 1990; it remarkably improved patient outcomes, leading to the nomenclature change of PBC in 2015, from primary biliary “cirrhosis” to primary biliary “cholangitis.” Nevertheless, 20–30% of patients exhibit an incomplete response to UDCA, resulting in significantly worse outcomes compared to those with a complete response. Therefore, improving the long-term outcomes of patients with an incomplete response to UDCA has been recognized as an unmet need. In addition, patients with PBC often suffer from a variety of debilitating symptoms, such as pruritus, fatigue and sicca syndrome, which significantly impair their health-related quality of life. Thus, appropriate management of these symptoms is currently regarded as another unmet need for PBC treatment. In this review, several compounds and drugs under clinical trials that can potentially solve these unmet needs are comprehensively discussed, and future directions of treatment policy of PBC are proposed for significantly improving long-term outcome as well as health-related quality of life of patients.

Lleo A, Wang GQ, Gershwin ME, Hirschfield GM. Primary biliary cholangitis. Lancet. 2020;396:1915–26. https://doi.org/10.1016/S0140-6736(20)31607-X.CrossRefPubMed

Lleo A, Jepsen P, Morenghi E, Carbone M, Moroni L, Battezzati PM, et al. Evolving trends in female to male incidence and male mortality of primary biliary cholangitis. Sci Rep. 2016;6:25906. https://doi.org/10.1038/srep25906.CrossRefPubMedPubMedCentral

Tanaka A, Mori M, Matsumoto K, Ohira H, Tazuma S, Takikawa H. Increase trend in the prevalence and male-to-female ratio of primary biliary cholangitis, autoimmune hepatitis, and primary sclerosing cholangitis in Japan. Hepatol Res. 2019;49:881–9. https://doi.org/10.1111/hepr.13342.CrossRefPubMed

Lleo A, Marzorati S, Anaya JM, Gershwin ME. Primary biliary cholangitis: a comprehensive overview. Hepatol Int. 2017;11:485–99. https://doi.org/10.1007/s12072-017-9830-1.CrossRefPubMed

Poupon RE, Balkau B, Eschwège E, Poupon R. A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC study group. N Engl J Med. 1991;324:1548–54. https://doi.org/10.1056/NEJM199105303242204.CrossRefPubMed

Poupon RE, Eschwège E, Poupon R. Ursodeoxycholic acid for the treatment of primary biliary cirrhosis. Interim analysis of a double-blind multicentre randomized trial. The UDCA-PBC study group. J Hepatol. 1990;11:16–21. https://doi.org/10.1016/0168-8278(90)90265-s.CrossRefPubMed

Beuers U, Gershwin ME, Gish RG, Invernizzi P, Jones DE, Lindor K, et al. Changing nomenclature for PBC: from “cirrhosis” to “cholangitis.” J Hepatol. 2015;63:1285–7. https://doi.org/10.1016/j.jhep.2015.06.031.CrossRefPubMed

European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu, European Association for the Study of the Liver. EASL clinical practice guidelines: the diagnosis and management of patients with primary biliary cholangitis. J Hepatol. 2017;67:145–72. https://doi.org/10.1016/j.jhep.2017.03.022

Lindor KD, Bowlus CL, Boyer J, et al. Primary biliary cholangitis: 2018 practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2019;69:394–419. https://doi.org/10.1002/hep.30145

10.

Nevens F, Andreone P, Mazzella G, Strasser SI, Bowlus C, Invernizzi P, et al. A placebo-controlled trial of obeticholic acid in primary biliary cholangitis. N Engl J Med. 2016;375:631–43. https://doi.org/10.1056/NEJMoa1509840.CrossRefPubMed

11.

Corpechot C, Chazouillères O, Rousseau A. Bezafibrate in primary biliary cholangitis. N Engl J Med. 2018;379:985. https://doi.org/10.1056/NEJMc1809061.CrossRefPubMed

12.

Tanaka A, Hirohara J, Nakano T, Matsumoto K, Chazouillères O, Takikawa H, et al. Association of bezafibrate with transplant-free survival in patients with primary biliary cholangitis. J Hepatol. 2021;75:565–71. https://doi.org/10.1016/j.jhep.2021.04.010.CrossRefPubMed

13.

Lleo A, Bowlus CL, Yang GX, Invernizzi P, Podda M, Van de Water J, et al. Biliary apotopes and anti-mitochondrial antibodies activate innate immune responses in primary biliary cirrhosis. Hepatology. 2010;52:987–98. https://doi.org/10.1002/hep.23783.CrossRefPubMed

14.

Lleo A, Selmi C, Invernizzi P, Podda M, Coppel RL, Mackay IR, et al. Apotopes and the biliary specificity of primary biliary cirrhosis. Hepatology. 2009;49:871–9. https://doi.org/10.1002/hep.22736.CrossRefPubMed

15.

Cordell HJ, Fryett JJ, Ueno K, Darlay R, Aiba Y, Hitomi Y, et al. An international genome-wide meta-analysis of primary biliary cholangitis: novel risk loci and candidate drugs. J Hepatol. 2021;75:572–81. https://doi.org/10.1016/j.jhep.2021.04.055.CrossRefPubMedPubMedCentral

16.

Beuers U, Hohenester S, de Buy Wenniger LJ, Kremer AE, Jansen PL, Elferink RP. The biliary HCO(3)(−) umbrella: a unifying hypothesis on pathogenetic and therapeutic aspects of fibrosing cholangiopathies. Hepatology. 2010;52:1489–96. https://doi.org/10.1002/hep.23810.CrossRefPubMed

17.

Banales JM, Sáez E, Uriz M, Sarvide S, Urribarri AD, Splinter P, et al. Up-regulation of microRNA 506 leads to decreased Cl−/HCO₃− anion exchanger 2 expression in biliary epithelium of patients with primary biliary cirrhosis. Hepatology. 2012;56:687–97. https://doi.org/10.1002/hep.25691.CrossRefPubMed

18.

Asselta R, Paraboschi EM, Gerussi A, Cordell HJ, Mells GF, Sandford RN, et al. X chromosome contribution to the genetic architecture of primary biliary cholangitis. Gastroenterology. 2021;160:2483-2495.e26. https://doi.org/10.1053/j.gastro.2021.02.061.CrossRefPubMed

19.

Poupon RE, Chrétien Y, Chazouillères O, Poupon R, Chwalow J. Quality of life in patients with primary biliary cirrhosis. Hepatology. 2004;40:489–94. https://doi.org/10.1002/hep.20276.CrossRefPubMed

20.

Newton JL, Bhala N, Burt J, Jones DE. Characterisation of the associations and impact of symptoms in primary biliary cirrhosis using a disease specific quality of life measure. J Hepatol. 2006;44:776–83. https://doi.org/10.1016/j.jhep.2005.12.012.CrossRefPubMed

21.

Selmi C, Gershwin ME, Lindor KD, Worman HJ, Gold EB, Watnik M, et al. Quality of life and everyday activities in patients with primary biliary cirrhosis. Hepatology. 2007;46:1836–43. https://doi.org/10.1002/hep.21953.CrossRefPubMed

22.

Mells GF, Pells G, Newton JL, Bathgate AJ, Burroughs AK, Heneghan MA, et al. Impact of primary biliary cirrhosis on perceived quality of life: the UK-PBC national study. Hepatology. 2013;58:273–83. https://doi.org/10.1002/hep.26365.CrossRefPubMed

23.

Dyson JK, Wilkinson N, Jopson L, Mells G, Bathgate A, Heneghan MA, et al. The inter-relationship of symptom severity and quality of life in 2055 patients with primary biliary cholangitis. Aliment Pharmacol Ther. 2016;44:1039–50. https://doi.org/10.1111/apt.13794.CrossRefPubMedPubMedCentral

24.

Yagi M, Tanaka A, Abe M, Namisaki T, Yoshiji H, Takahashi A, et al. Symptoms and health-related quality of life in Japanese patients with primary biliary cholangitis. Sci Rep. 2018;8:12542. https://doi.org/10.1038/s41598-018-31063-8.CrossRefPubMedPubMedCentral

25.

Beuers U, Wolters F, Oude Elferink RPJ. Mechanisms of pruritus in cholestasis: understanding and treating the itch. Nat Rev Gastroenterol Hepatol. 2023;20:26–36. https://doi.org/10.1038/s41575-022-00687-7.CrossRefPubMed

26.

Düll MM, Kremer AE. Evaluation and management of pruritus in primary biliary cholangitis. Clin Liver Dis. 2022;26:727–45. https://doi.org/10.1016/j.cld.2022.06.009.CrossRefPubMed

27.

Lynch EN, Campani C, Innocenti T, Dragoni G, Biagini MR, Forte P, et al. Understanding fatigue in primary biliary cholangitis: from pathophysiology to treatment perspectives. World J Hepatol. 2022;14:1111–9. https://doi.org/10.4254/wjh.v14.i6.1111.CrossRefPubMedPubMedCentral

28.

Phaw NA, Leighton J, Dyson JK, Jones DE. Managing cognitive symptoms and fatigue in cholestatic liver disease. Expert Rev Gastroenterol Hepatol. 2021;15:235–41. https://doi.org/10.1080/17474124.2021.1844565.CrossRefPubMed

29.

Harms MH, van Buuren HR, Corpechot C, Thorburn D, Janssen HLA, Lindor KD, et al. Ursodeoxycholic acid therapy and liver transplant-free survival in patients with primary biliary cholangitis. J Hepatol. 2019;71:357–65. https://doi.org/10.1016/j.jhep.2019.04.001.CrossRefPubMed

30.

Lindor KD, Bowlus CL, Boyer J, Levy C, Mayo M. Primary biliary cholangitis: 2018 practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2019;69:394–419. https://doi.org/10.1002/hep.30145.CrossRefPubMed

31.

Lindor KD, Bowlus CL, Boyer J, Levy C, Mayo M. Primary biliary cholangitis: 2021 practice guidance update from the American Association for the Study of Liver Diseases. Hepatology. 2022;75:1012–3. https://doi.org/10.1002/hep.32117.CrossRefPubMed

32.

John BV, Schwartz K, Levy C, et al. Impact of obeticholic acid exposure on decompensation and mortality in primary biliary cholangitis and cirrhosis. Hepatol Commun. 2021;5:1426–36. https://doi.org/10.1002/hep4.1720.CrossRefPubMedPubMedCentral

33.

De Vincentis A, D’Amato D, Cristoferi L, et al. Predictors of serious adverse events and non-response in cirrhotic patients with primary biliary cholangitis treated with obeticholic acid. Liver Int. 2022;42:2453–65. https://doi.org/10.1111/liv.15386.CrossRefPubMedPubMedCentral

34.

Roberts SB, Ismail M, Kanagalingam G, et al. Real-world effectiveness of obeticholic acid in patients with primary biliary cholangitis. Hepatol Commun. 2020;4:1332–45. https://doi.org/10.1002/hep4.1518.CrossRefPubMedPubMedCentral

35.

D’Amato D, De Vincentis A, Malinverno F, et al. Real-world experience with obeticholic acid in patients with primary biliary cholangitis. JHEP Rep (Online). 2021;3: 100248. https://doi.org/10.1016/j.jhepr.2021.100248.CrossRef

36.

Gomez E, Garcia Buey L, Molina E, et al. Effectiveness and safety of obeticholic acid in a Southern European multicentre cohort of patients with primary biliary cholangitis and suboptimal response to ursodeoxycholic acid. Aliment Pharmacol Ther. 2021;53:519–30. https://doi.org/10.1111/apt.16181.CrossRefPubMed

37.

Harms MH, Hirschfield GM, Floreani A, et al. Obeticholic acid is associated with improvements in AST-to-platelet ratio index and GLOBE score in patients with primary biliary cholangitis. JHEP Rep (Online). 2021;3: 100191. https://doi.org/10.1002/hep.32117.CrossRef

38.

Murillo Perez CF, Fisher H, Hiu S, Kareithi D, Adekunle F, Mayne T, et al. Greater transplant-free survival in patients receiving obeticholic acid for primary biliary cholangitis in a clinical trial setting compared to real-world external controls. Gastroenterology. 2022;163:1630-1642.e3. https://doi.org/10.1053/j.gastro.2022.08.054.CrossRefPubMed

39.

Honda A, Ikegami T, Nakamuta M, Miyazaki T, Iwamoto J, Hirayama T, et al. Anti-cholestatic effects of bezafibrate in patients with primary biliary cirrhosis treated with ursodeoxycholic acid. Hepatology. 2013;57:1931–41. https://doi.org/10.1002/hep.26018.CrossRefPubMed

40.

Iwasaki S, Tsuda K, Ueta H. Bezafibrate may have a beneficial effect in pre-cirrhotic primary biliary cirrhosis. Hepatol Res. 1999;16:12–8. https://doi.org/10.1016/S1386-6346(99)00033-9.CrossRef

41.

Corpechot C, Chazouillères O, Rousseau A, Le Gruyer A, Habersetzer F, Mathurin P, et al. A placebo-controlled trial of bezafibrate in primary biliary cholangitis. N Engl J Med. 2018;378:2171–81. https://doi.org/10.1056/NEJMoa1714519.CrossRefPubMed

42.

de Vries E, Bolier R, Goet J, Parés A, Verbeek J, de Vree M, et al. Fibrates for itch (FITCH) in fibrosing cholangiopathies: a double-blind, randomized, placebo-controlled trial. Gastroenterology. 2021;160:734-743.e6. https://doi.org/10.1053/j.gastro.2020.10.001.CrossRefPubMed

43.

Hosonuma K, Sato K, Yamazaki Y, Yanagisawa M, Hashizume H, Horiguchi N, et al. A prospective randomized controlled study of long-term combination therapy using ursodeoxycholic acid and bezafibrate in patients with primary biliary cirrhosis and dyslipidemia. Am J Gastroenterol. 2015;110:423–31. https://doi.org/10.1038/ajg.2015.20.CrossRefPubMed

44.

Matsumoto K, Hirohara J, Takeuchi A, Miura R, Asaoka Y, Nakano T, et al. Determinants of the effectiveness of bezafibrate combined with ursodeoxycholic acid in patients with primary biliary cholangitis. Hepatol Res. 2023. https://doi.org/10.1111/hepr.13931.CrossRefPubMed

45.

Cheung AC, Lapointe-Shaw L, Kowgier M, Meza-Cardona J, Hirschfield GM, Janssen HL, et al. Combined ursodeoxycholic acid (UDCA) and fenofibrate in primary biliary cholangitis patients with incomplete UDCA response may improve outcomes. Aliment Pharmacol Ther. 2016;43:283–93. https://doi.org/10.1111/apt.13465.CrossRefPubMed

46.

Soret PA, Lam L, Carrat F, Smets L, Berg T, Carbone M, et al. Combination of fibrates with obeticholic acid is able to normalise biochemical liver tests in patients with difficult-to-treat primary biliary cholangitis. Aliment Pharmacol Ther. 2021;53:1138–46. https://doi.org/10.1111/apt.16336.CrossRefPubMed

47.

Yagi M, Tanaka A, Namisaki T, Takahashi A, Abe M, Honda A, et al. Is patient-reported outcome improved by nalfurafine hydrochloride in patients with primary biliary cholangitis and refractory pruritus? A post-marketing, single-arm, prospective study. J Gastroenterol. 2018;53:1151–8. https://doi.org/10.1007/s00535-018-1465-z.CrossRefPubMed

48.

Hirschfield GM, Beuers U, Kupcinskas L, Ott P, Bergquist A, Färkkilä M, et al. A placebo-controlled randomised trial of budesonide for PBC following an insufficient response to UDCA. J Hepatol. 2021;74:321–9. https://doi.org/10.1016/j.jhep.2020.09.011.CrossRefPubMed

49.

de Graaf KL, Lapeyre G, Guilhot F, Ferlin W, Curbishley SM, Carbone M, et al. NI-0801, an anti-chemokine (C-X-C motif) ligand 10 antibody, in patients with primary biliary cholangitis and an incomplete response to ursodeoxycholic acid. Hepatol Commun. 2018;2:492–503. https://doi.org/10.1002/hep4.1170.CrossRefPubMedPubMedCentral

50.

Tanaka A, Abe M, Namisaki T, et al. Efficacy and Safety of E6011, anti-human fractalkine monoclonal antibody, in patients with primary biliary cholangitis with an incomplete response to ursodeoxycholic acid: a placebo-controlled double-blind comparison Phase 2 study. Hepatology. 2019;70:767A.

51.

Bowlus CL, Yang GX, Liu CH, Johnson CR, Dhaliwal SS, Frank D, et al. Therapeutic trials of biologics in primary biliary cholangitis: an open label study of abatacept and review of the literature. J Autoimmun. 2019;101:26–34. https://doi.org/10.1016/j.jaut.2019.04.005.CrossRefPubMed

52.

Hirschfield GM, Gershwin ME, Strauss R, Mayo MJ, Levy C, Zou B, et al. Ustekinumab for patients with primary biliary cholangitis who have an inadequate response to ursodeoxycholic acid: a proof-of-concept study. Hepatology. 2016;64:189–99. https://doi.org/10.1002/hep.28359.CrossRefPubMed

53.

Schramm C, Wedemeyer H, Mason A, Hirschfield GM, Levy C, Kowdley KV, et al. Farnesoid X receptor agonist tropifexor attenuates cholestasis in a randomised trial in patients with primary biliary cholangitis. JHEP Rep. 2022;4: 100544. https://doi.org/10.1016/j.jhepr.2022.100544.CrossRefPubMedPubMedCentral

54.

Kowdley KV, Minuk GY, Pagadala MR, et al. The nonsteroidal farnesoid X receptor (FXR) agonist cilofexor improves liver biochemistry in patients with primary biliary cholangitis (PBC): a phase 2, randomized, placebo-controlled trial. Hepatology. 2019;70:31A-A32.

55.

Kowdley KV, Bonder A, Heneghan MA, et al. Final data of the phase 2a intrepid study with edp-305, a non-bile acid farnesoid X receptor (FXR) agonist. Hepatology. 2020;72:746A-A747.

56.

Colapietro F, Gershwin ME, Lleo A. PPAR agonists for the treatment of primary biliary cholangitis: old and new tales. J Transl Autoimmun. 2023;6: 100188. https://doi.org/10.1016/j.jtauto.2023.100188.CrossRefPubMedPubMedCentral

57.

Tanaka N, Honda A. Pemafibrate for primary biliary cholangitis with dyslipidemia: a proposal of a new treatment from Japan. Hepatol Res. 2022;52:495–6. https://doi.org/10.1111/hepr.13770.CrossRefPubMed

58.

Dohmen K, Onohara SY, Harada S. Effects of switching from fenofibrate to pemafibrate for asymptomatic primary biliary cholangitis. Korean J Gastroenterol. 2021;78:227–34. https://doi.org/10.4166/kjg.2021.092.CrossRefPubMed

59.

Joshita S, Umemura T, Yamashita Y, Sugiura A, Yamazaki T, Fujimori N, et al. Biochemical and plasma lipid responses to pemafibrate in patients with primary biliary cholangitis. Hepatol Res. 2019;49:1236–43. https://doi.org/10.1111/hepr.13361.CrossRefPubMed

60.

Yamaguchi M, Asano T, Arisaka T, Mashima H, Irisawa A, Tamano M. Effects of pemafibrate on primary biliary cholangitis with dyslipidemia. Hepatol Res. 2022;52:522–31. https://doi.org/10.1111/hepr.13747.CrossRefPubMed

61.

Jones D, Boudes PF, Swain MG, Bowlus CL, Galambos MR, Bacon BR, et al. Seladelpar (MBX-8025), a selective PPAR-delta agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study. Lancet Gastroenterol Hepatol. 2017;2:716–26. https://doi.org/10.1016/S2468-1253(17)30246-7.CrossRefPubMed

62.

Bowlus CL, Galambos MR, Aspinall RJ, Hirschfield GM, Jones DEJ, Dörffel Y, et al. A phase II, randomized, open-label, 52-week study of seladelpar in patients with primary biliary cholangitis. J Hepatol. 2022;77:353–64. https://doi.org/10.1016/j.jhep.2022.02.033.CrossRefPubMed

63.

Hirschfield GM, Shiffman ML, Gulamhusein A, Kowdley KV, Vierling JM, Levy C, et al. Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled study. Hepatology. 2023;78:397–415. https://doi.org/10.1097/HEP.0000000000000395.CrossRefPubMed

64.

Watkins P. An independent blinded review of suspected druginduced liver injury (DILI) in nonalcoholic steatohepatitis (NASH) patients by a panel of pathologists and hepatologists: lessons learned from the seladelpar hepatoxicity review committee (SHRC). 2022; Available from: https://www.postersessiononline.eu/173580348_eu/congresos/ILC2021/aula/-PO_1504_ILC2021.pdf.

65.

Schattenberg JM, Pares A, Kowdley KV, Heneghan MA, Caldwell S, Pratt D, et al. A randomized placebo-controlled trial of elafibranor in patients with primary biliary cholangitis and incomplete response to UDCA. J Hepatol. 2021;74:1344–54. https://doi.org/10.1016/j.jhep.2021.01.013.CrossRefPubMed

66.

Vuppalanchi R, Caldwell SH, Pyrsopoulos N, deLemos AS, Rossi S, Levy C, et al. Proof-of-concept study to evaluate the safety and efficacy of saroglitazar in patients with primary biliary cholangitis. J Hepatol. 2022;76:75–85. https://doi.org/10.1016/j.jhep.2021.08.025.CrossRefPubMed

67.

Invernizzi P, Carbone M, Jones D, Levy C, Little N, Wiesel P, et al. Setanaxib, a first-in-class selective NADPH oxidase 1/4 inhibitor for primary biliary cholangitis: a randomized, placebo-controlled, phase 2 trial. Liver Int. 2023;43:1507–22. https://doi.org/10.1111/liv.15596.CrossRefPubMed

68.

Levy C, Kendrick S, Bowlus CL, Tanaka A, Jones D, Kremer AE, et al. GLIMMER: a randomized phase 2b dose-ranging trial of linerixibat in primary biliary cholangitis patients with pruritus. Clin Gastroenterol Hepatol. 2023;21:1902-1912.e13. https://doi.org/10.1016/j.cgh.2022.10.032.CrossRefPubMed

69.

Mayo MJ, Pockros PJ, Jones D, Bowlus CL, Levy C, Patanwala I, et al. A randomized, controlled, Phase 2 study of maralixibat in the treatment of itching associated with primary biliary cholangitis. Hepatol Commun. 2019;3:365–81. https://doi.org/10.1002/hep4.1305.CrossRefPubMedPubMedCentral

70.

Silveira MG, Gossard AA, Stahler AC, Jorgensen RA, Petz JL, Ali AH, et al. A randomized, placebo-controlled clinical trial of efficacy and safety: modafinil in the treatment of fatigue in patients with primary biliary cirrhosis. Am J Ther. 2017;24:e167–76. https://doi.org/10.1097/MJT.0000000000000387.CrossRefPubMed

71.

Khanna A, Jopson L, Howel D, Bryant A, Blamire A, Newton JL, et al. Rituximab is ineffective for treatment of fatigue in primary biliary cholangitis: a phase 2 randomized controlled trial. Hepatology. 2019;70:1646–57. https://doi.org/10.1002/hep.30099.CrossRefPubMed

72.

Corpechot C, Abenavoli L, Rabahi N, Chrétien Y, Andréani T, Johanet C, et al. Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis. Hepatology. 2008;48:871–7. https://doi.org/10.1002/hep.22428.CrossRefPubMed

73.

Corpechot C, Chazouillères O, Poupon R. Early primary biliary cirrhosis: biochemical response to treatment and prediction of long-term outcome. J Hepatol. 2011;55:1361–7. https://doi.org/10.1016/j.jhep.2011.02.031.CrossRefPubMed

74.

Kuiper EM, Hansen BE, de Vries RA, den Ouden-Muller JW, van Ditzhuijsen TJ, Haagsma EB, et al. Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid. Gastroenterology. 2009;136:1281–7. https://doi.org/10.1053/j.gastro.2009.01.003.CrossRefPubMed

75.

Kumagi T, Guindi M, Fischer SE, Arenovich T, Abdalian R, Coltescu C, et al. Baseline ductopenia and treatment response predict long-term histological progression in primary biliary cirrhosis. Am J Gastroenterol. 2010;105:2186–94. https://doi.org/10.1038/ajg.2010.216.CrossRefPubMed

76.

Parés A, Caballería L, Rodés J. Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic acid. Gastroenterology. 2006;130:715–20. https://doi.org/10.1053/j.gastro.2005.12.029.CrossRefPubMed

77.

Carbone M, Sharp SJ, Flack S, Paximadas D, Spiess K, Adgey C, et al. The UK-PBC risk scores: derivation and validation of a scoring system for long-term prediction of end-stage liver disease in primary biliary cholangitis. Hepatology. 2016;63:930–50. https://doi.org/10.1002/hep.28017.CrossRefPubMed

78.

Lammers WJ, Hirschfield GM, Corpechot C, Nevens F, Lindor KD, Janssen HL, et al. Development and validation of a scoring system to predict outcomes of patients with primary biliary cirrhosis receiving ursodeoxycholic acid therapy. Gastroenterology. 2015;149:1804-1812.e4. https://doi.org/10.1053/j.gastro.2015.07.061.CrossRefPubMed

79.

Lammers WJ, van Buuren HR, Hirschfield GM, Janssen HL, Invernizzi P, Mason AL, et al. Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow-up study. Gastroenterology. 2014;147:1338:e5. https://doi.org/10.1053/j.gastro.2014.08.029.CrossRef

80.

Murillo Perez CF, Harms MH, Lindor KD, Van Buuren HR, Hirschfield GM, Corpechot C, et al. Goals of treatment for improved survival in primary biliary cholangitis: treatment target should be bilirubin within the normal range and normalization of alkaline phosphatase. Am J Gastroenterol. 2020;115:1066–74. https://doi.org/10.14309/ajg.0000000000000557.CrossRefPubMed

81.

Corpechot C, Lemoinne S, Soret PA, Hansen B, Hirschfield G, Gulamhusein A, et al. Adequate vs. deep response to UDCA in PBC: to what extent and under what conditions is normal ALP level associated with complication-free survival gain? Hepatology. 2023. https://doi.org/10.1097/HEP.0000000000000529.CrossRefPubMed

82.

Murillo Perez CF, Ioannou S, Hassanally I, Trivedi PJ, Corpechot C, van der Meer AJ, et al. Optimizing therapy in primary biliary cholangitis: alkaline phosphatase at six months identifies one-year non-responders and predicts survival. Liver Int. 2023;43:1497–506. https://doi.org/10.1111/liv.15592.CrossRefPubMed

83.

Danaei G, Rodríguez LA, Cantero OF, Logan R, Hernán MA. Observational data for comparative effectiveness research: an emulation of randomised trials of statins and primary prevention of coronary heart disease. Stat Methods Med Res. 2013;22:70–96. https://doi.org/10.1177/0962280211403603.CrossRefPubMed

84.

Food and Drug Administration. Submitting documents using real-world data and real-world evidence to FDA for drug and biological products guidance for industry. https://www.fda.gov/media/124795/download. Accessed 24 Aug 2023.

85.

Corpechot C, Carrat F, Gaouar F, Chau F, Hirschfield G, Gulamhusein A, et al. Liver stiffness measurement by vibration-controlled transient elastography improves outcome prediction in primary biliary cholangitis. J Hepatol. 2022;77:1545–53. https://doi.org/10.1016/j.jhep.2022.06.017.CrossRefPubMed

86.

Carbone M, Nardi A, Flack S, Carpino G, Varvaropoulou N, Gavrila C, et al. Pretreatment prediction of response to ursodeoxycholic acid in primary biliary cholangitis: development and validation of the UDCA Response Score. Lancet Gastroenterol Hepatol. 2018;3:626–34. https://doi.org/10.1016/S2468-1253(18)30163-8.CrossRefPubMedPubMedCentral

87.

Jacoby A, Rannard A, Buck D, Bhala N, Newton JL, James OF, et al. Development, validation, and evaluation of the PBC-40, a disease specific health related quality of life measure for primary biliary cirrhosis. Gut. 2005;54:1622–9. https://doi.org/10.1136/gut.2005.065862.CrossRefPubMedPubMedCentral

88.

Montali L, Tanaka A, Riva P, Takahashi H, Cocchi C, Ueno Y, et al. A short version of a HRQoL questionnaire for Italian and Japanese patients with primary biliary cirrhosis. Dig Liver Dis. 2010;42:718–23. https://doi.org/10.1016/j.dld.2010.01.004. (Epub ahead of print).CrossRefPubMed

89.

Alrubaiy L, Mells G, Flack S, Bosomworth H, Hutchings H, Williams J, et al. PBC-10: a short quality of life measure for clinical screening in primary biliary cholangitis. Aliment Pharmacol Ther. 2019;50:1223–31. https://doi.org/10.1111/apt.15554.CrossRefPubMed

Title: New Therapies on the Horizon for Primary Biliary Cholangitis
Author: Atsushi Tanaka
Publication date: 12-12-2023
Publisher: Springer International Publishing
Keywords: Primary Biliary Cholangitis
Fibrates
Pruritus
Bezafibrate
Published in: Drugs / Issue 1/2024
Print ISSN: 0012-6667
Electronic ISSN: 1179-1950
DOI: https://doi.org/10.1007/s40265-023-01979-1

At a glance: The STEP trials

Springer Medicine

New Therapies on the Horizon for Primary Biliary Cholangitis

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2024

Comment on: “Recent Human Papillomavirus Vaccination is Associated with a Lower Risk of COVID-19: A US Database Cohort Study”

Spesolimab for the Treatment of Generalized Pustular Psoriasis

Reply to the Comments on “Recent Human Papillomavirus Vaccination is Associated with a Lower Risk of COVID-19: A US Database Cohort Study”

Zilucoplan: First Approval

Pharmacological Treatments of Temporomandibular Disorders: A Systematic Review Including a Network Meta-Analysis

Targeting KRAS-Mutated Gastrointestinal Malignancies with Small-Molecule Inhibitors: A New Generation of Breakthrough Therapies